Result of AGM
By Sharecast
Date: Monday 29 Dec 2025
SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Group")
Result of Annual General Meeting
29 December 2025 - SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), a life science company focused on skin health, held its Annual General Meeting today and all resolutions were passed.
Resolution | Votes For | Votes Against | Votes Withheld | ||
1. To receive the annual report and accounts | 88,024,558 | 83.50% | 17,391,981 | 16.50% | 722,198 |
2. To re-appoint Gravita as auditor | 96,998,314 | 92.15% | 8,266,920 | 7.85% | 873,503 |
3. To authorise Directors to determine Auditors renumeration | 97,093,358 | 92.13% | 8,296,876 | 7.87% | 748,503 |
4. To authorise the Directors to allot relevant securities | 85,828,638 | 80.90% | 20,268,099 | 19.10% | 42,000 |
5. To authorise the Directors to allot equity securities for cash without a pre-emptive offer to shareholders | 85,771,888 | 80.84% | 20,324,849 | 19.16% | 42,000 |
6. To authorise the Directors to allot equity securities for cash in relation to an acquisition of other capital investment | 85,782,499 | 81.34% | 19,682,546 | 18.66% | 673,692 |
An electronic copy of the Annual Report and Accounts is available and the results of the AGM will be available on the Company's website in due course at www.skinbiotherapeutics.com/investor-relations.
-Ends-
For more information please contact:
SkinBioTherapeutics plc Stuart J. Ashman, CEO | +44 (0) 191 495 7325
|
Singer Capital Markets (Nominated Adviser & Broker) Philip Davies | +44 (0) 020 7496 3000
|
Vigo Consulting (financial press) Rozi Morris, Melanie Toyne-Sewell | +44 (0) 20 7390 0230 SkinBio@vigoconsulting.com |
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.
The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix®) and food supplements that harness the gut-skin axis (AxisBiotix™). The cosmetic pillar has a partnership with Croda plc where SkinBiotix® is being used as an active skin ingredient with the Croda trade name, Zenakine™. The AxisBiotix™ pillar has a range of products targeting the symptoms of inflammatory skin conditions, being sold directly and via Amazon, and on the High Street in selected Superdrug Stores plc stores.
The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skincare and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products.
The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN